Guardian Investment Management lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 11.0% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,332 shares of the company's stock after selling 2,140 shares during the quarter. Johnson & Johnson accounts for approximately 2.3% of Guardian Investment Management's investment portfolio, making the stock its 12th biggest position. Guardian Investment Management's holdings in Johnson & Johnson were worth $2,873,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of the business. Tallon Kerry Patrick bought a new position in shares of Johnson & Johnson in the fourth quarter worth $290,000. Brighton Jones LLC grew its stake in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares in the last quarter. Hudson Value Partners LLC grew its stake in Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after buying an additional 1,022 shares in the last quarter. Asahi Life Asset Management CO. LTD. increased its holdings in Johnson & Johnson by 5.7% in the 4th quarter. Asahi Life Asset Management CO. LTD. now owns 13,466 shares of the company's stock valued at $1,947,000 after buying an additional 723 shares during the period. Finally, SRS Capital Advisors Inc. raised its position in shares of Johnson & Johnson by 10.9% in the 4th quarter. SRS Capital Advisors Inc. now owns 17,161 shares of the company's stock valued at $2,482,000 after buying an additional 1,682 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
JNJ has been the topic of several analyst reports. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Royal Bank Of Canada restated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday, June 5th. Bank of America decreased their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price target for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Finally, Morgan Stanley lifted their target price on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $170.88.
Get Our Latest Stock Report on JNJ
Johnson & Johnson Stock Up 0.2%
Shares of Johnson & Johnson stock traded up $0.34 during trading on Thursday, reaching $155.90. 3,482,521 shares of the company traded hands, compared to its average volume of 8,027,945. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The firm has a market capitalization of $375.11 billion, a PE ratio of 17.34, a P/E/G ratio of 2.36 and a beta of 0.41. The company has a 50 day moving average price of $153.63 and a 200-day moving average price of $153.88. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.34%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
